Home » Stocks » ASND

Ascendis Pharma A/S (ASND)

Stock Price: $130.25 USD 2.03 (1.58%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $127.00 -3.25 (-2.50%) Jun 11, 7:32 PM
Market Cap 7.01B
Revenue (ttm) 6.44M
Net Income (ttm) -492.27M
Shares Out 53.83M
EPS (ttm) -9.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $130.25
Previous Close $128.22
Change ($) 2.03
Change (%) 1.58%
Day's Open 127.36
Day's Range 125.96 - 130.33
Day's Volume 203,772
52-Week Range 119.11 - 183.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021 Prescription Drug User Fee Act (PDUFA) goal date extended by three months...

1 day ago - GlobeNewsWire

1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China...

1 week ago - PRNewsWire

Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 0 2 0 1 Indifferent ...

1 week ago - Benzinga

Online event to include a live reading by Children's Author, Ariana Feiner, whose short film documentary, A Story of Courage, has won 24 international awards Online event to include a live reading by Ch...

2 weeks ago - GlobeNewsWire

– Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021 –

2 weeks ago - GlobeNewsWire

COPENHAGEN, Denmark, May 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates tha...

3 weeks ago - GlobeNewsWire

– Marks next step to bring the potential first ever hormone replacement therapy for hypoparathyroidism to Japan – – Marks next step to bring the potential first ever hormone replacement therapy for hypo...

1 month ago - GlobeNewsWire

Ascendis Pharma A/S (NASDAQ: ASND) has announced preliminary 58-week results from the continuing open-label extension (OLE) portion of the Phase 2 PaTH Forward Trial evaluating TransCon PTH in adult sub...

1 month ago - Benzinga

– 58 subjects continue in the open-label extension study for TransCon PTH –

1 month ago - GlobeNewsWire

COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, t...

1 month ago - GlobeNewsWire

COPENHAGEN, Denmark, May 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates tha...

1 month ago - GlobeNewsWire

COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs,...

1 month ago - GlobeNewsWire

COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates t...

2 months ago - GlobeNewsWire

Clinical data demonstrate the potential of TransCon PTH as a hormone replacement therapy for adults with hypoparathyroidism Clinical data demonstrate the potential of TransCon PTH as a hormone replaceme...

2 months ago - GlobeNewsWire

COPENHAGEN, Denmark, March 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates t...

2 months ago - GlobeNewsWire

– Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track –

3 months ago - GlobeNewsWire

COPENHAGEN, Denmark, March 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs...

3 months ago - GlobeNewsWire

On Wednesday, March 10, Ascendis Pharma (NASDAQ:ASND) will release its latest earnings report. Benzinga's outlook for Ascendis Pharma is included in the following report.

3 months ago - Benzinga

COPENHAGEN, Denmark, March 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates t...

3 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, ...

3 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...

3 months ago - GlobeNewsWire

If you screen the market for stocks that have a current ratio higher than 2 and more working capital than long-term debt, as Benjamin Graham, the pioneer of value investing, recommended, the chances tha...

Other stocks mentioned: GH, TPTX
4 months ago - GuruFocus

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experien...

Other stocks mentioned: KALV
4 months ago - Business Wire

COPENHAGEN, Denmark, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...

5 months ago - GlobeNewsWire

– Advances Vision 3x3 to extend global clinical and commercial reach –

5 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...

5 months ago - GlobeNewsWire

- TransCon TLR7/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response  -

5 months ago - GlobeNewsWire

Investors need to pay close attention to Ascendis Pharma (ASND) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting –

5 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...

6 months ago - GlobeNewsWire

Ascendis has a PDUFA date of June 25, 2021 for its lead indication. However, what makes this pre-market stage company so valuable is its TransCon platform.

6 months ago - Seeking Alpha

Ascendis Pharma's (ASND) CEO Jan Mikkelsen on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

– Event will provide an overview of how A s cendis is applying its TransCon ™ technology platform and its unique algorithm for product innovation to the therapeutic area of o ncology –

7 months ago - GlobeNewsWire

Shares of Ascendis Pharma (NASDAQ:ASND) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 365.52% over the past year to ($2.70), whi...

7 months ago - Benzinga

– European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA)  f or TransCon TM hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) –

7 months ago - GlobeNewsWire

Ascendis (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

7 months ago - Zacks Investment Research

COPENHAGEN, Denmark, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs,...

7 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs,...

7 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, ...

7 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs,...

7 months ago - GlobeNewsWire

Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.

8 months ago - Zacks Investment Research

- Six-month data from PaTH Forward open-label extension support potential use of  TransCon PTH as a hormone replacement therapy for adult hypoparathyroidism –

8 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical need...

8 months ago - GlobeNewsWire

– Introduces #Together4Growth to increase awareness of children’s growth disorders, including a four-question Growth Quiz to help parents identify signs and symptoms –

8 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical nee...

9 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical need...

9 months ago - GlobeNewsWire

Ascendis Pharma sees its Relative Strength Rating reach the 80-plus level. The post Stocks Showing Rising Market Leadership: Ascendis Pharma Earns 82 RS Rating appeared first on Investor's Business Daily.

9 months ago - Investors Business Daily

COPENHAGEN, Denmark, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that uses its novel TransCon technologies to address unmet medical needs, announ...

9 months ago - GlobeNewsWire

– Prescription Drug User Fee Act (PDUFA) target action date of June 25, 2021 –

9 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical need...

9 months ago - GlobeNewsWire

About ASND

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorpo... [Read more...]

Industry
Biotechnology
IPO Date
Jan 28, 2015
CEO
Jan Moeller Mikkelsen
Employees
482
Stock Exchange
NASDAQ
Ticker Symbol
ASND
Full Company Profile

Financial Performance

In 2020, ASND's revenue was 6.95 million, a decrease of -48.01% compared to the previous year's 13.38 million. Losses were -418.96 million, 92.2% more than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price forecast is 195.40, which is an increase of 50.02% from the latest price.

Price Target
$195.40
(50.02% upside)
Analyst Consensus: Strong Buy